TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Decrease in apical diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of ibuprofen tablets used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence and intensity of propofol injection pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total incidence of distal embolization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blush score 3 acquisition rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood loss during vaginal hysterectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean blood pressure increase at 5 minutes after injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative morphine use
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of women reporting sexual activity
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: pain with sexual activity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymphocyte count density (LCD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Functional improvements (gait, stamina, motivation)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Serum LH concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum FSH concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: cardiovascular profile improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Biochemical FSV insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: brachial reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma Trolox equivalent antioxidant capacity (TEAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma thiobarbituric acid-reactive substances (TBARS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long axis shortening mean (MAPSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak lateral systolic velocity (S' lateral)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak lateral early diastolic velocity (E' lateral)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Push-up test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enjoyment of the lesson
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Dynamic balance increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant insertion torque superior to 35 Ncm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Marginal bone levels at implant insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean high-density lipoprotein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endurance Walk Test (EWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leicester Cough Questionnaire (LCQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: severe neonatal morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intrapartum fetal death
Endpoint domain: Mortality/survival
Primary endpoint: Speed of cerebral effect of a drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: sensory sural amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: motor nerve amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: motor nerve velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: crown/implant failures
Endpoint domain: Adverse events/effects
Primary endpoint: perceived helpfulness of medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 24-hour double-label recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: falls injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiac events during hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: plasma levels of myristic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma levels of pentadecanoic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma levels of margaric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CD-sens values to peanut
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IgE-antibody levels to Ara h 1, 2 and 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: DBPCFC results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of children who developed adverse post-extubation respiratory events
Endpoint domain: Adverse events/effects
Primary endpoint: Overall incidence of adverse postoperative respiratory events
Endpoint domain: Adverse events/effects
Primary endpoint: age-corrected constant score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: embryonic/fetal demise
Endpoint domain: Mortality/survival
Primary endpoint: embryonic/fetal heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pulsatility index (PI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: HbA1c change from baseline to month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: freedom from local recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ovarian stromal flow indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum venodilation (Emax) induced by isoproterenol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Infusion rate of isoproterenol required to induce 50% of maximum venodilation (ED50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: major ischemic cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy of S-etodolac in osteoarthritis treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Tolerability of S-etodolac
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of S-etodolac
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative GPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: asthma knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: controller device use skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak glucagon (pGON)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: incremental glucagon (ΔGON)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Occurrence of cellophane membranes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation of school age children in the trial
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Visualization of axillary lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Visualization of parasternal lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Observation of intramammary hot spots
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Reduction in pain at placement of the tenaculum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of shoulder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vasovagal reaction rate
Endpoint domain: Adverse events/effects
Primary endpoint: ALT elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: miR-122 increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: necrosis biomarkers elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: metal artifact degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean flow velocities in the middle cerebral artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean flow velocities in the internal carotid artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Production of nitric oxide in nasal lavage fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: s-energy levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mood measures
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: cognitive measures
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Risk of fatal prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: SDASI improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qualified success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Complications requiring surgical intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Colonic motility index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: High-amplitude propagated contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean reduction in sitting BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients meeting diastolic BP response criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage of patients with ocular manifestations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients with visual acuity loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sodium clearance (CL(Na))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fractional distal reabsorption of sodium (FDR(Na))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Optimal BADDS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe toxicity (grade 3-4 diarrhea and stomatitis)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical cure by Day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral yeast eradication rate on Day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Higher ventricular heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prolonged PR interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in ridge height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk reduction of the composite of cardiovascular death, stroke and MI
Endpoint domain: Mortality/survival
Primary endpoint: relief from heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Average intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Risk of severe and long-standing hypotony
Endpoint domain: Adverse events/effects
Primary endpoint: median population clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the plasma drug concentration-time curve target attainment rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic venous thromboembolism incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Night vision tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate response to stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic blood pressure response to stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of Recovery-40 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day health care use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean hair reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard deviation of QT:RR regression values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean change from baseline in weekly itch severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global communication skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Return to work after acute myocardial infarction
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Time to complete oral feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of normal children at 3 and 6 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: anxiety as indexed by the Beck's anxiety inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Packed cell volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in trait anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean effective flow rates (Qbeff, mL/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insertion complications
Endpoint domain: Adverse events/effects
Primary endpoint: in vivo spider fear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived danger
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of hs-CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Combined incidence of death, myocardial infarction, and need for revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Sedation levels in PACU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine requirement by PCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of FEV1 percent predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement of PC20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of parenchymal brain tissue injuries
Endpoint domain: Adverse events/effects
Primary endpoint: CLOSATS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global rating score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End-product score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median time to maximum plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in amygdala and hippocampus activation during emotion identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: plasma NO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma ET levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak response as percentage fall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in BSS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1st half very high intensity running mean speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2nd half very high intensity running distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postgame aspartate aminotransferase (AST) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discrimination of normal from malignant ovarian tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically relevant adverse interactions
Endpoint domain: Adverse events/effects
Primary endpoint: Measured menstrual blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete amenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HF-WBRT utilisation rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: DNA methylation of p16, MLH1, and MGMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Naming accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tobacco use abstinence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intraplatelet cGMP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma ET-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Behavioral skills for negotiating prevention and risk reduction
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Muscle CSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risky sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low MGMT expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interval to second surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: CA125 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: frequency of respiratory distress syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: use of oxygen at age 28 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: pain post-immunization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight regain percentage (WR%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: favorable outcome evaluated by survival without major neurological damage
Endpoint domain: Mortality/survival
Primary endpoint: changes in flow velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Uterine artery resistance index (RI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Identification and initiation of care for pre-eclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Total serum HCY levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: medial tibial cartilage volume loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: BML size increase in the medial compartment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sensitivity and specificity for TFCC injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in any lifetime alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in progression to frequent alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in progression to heavy alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Solid gastric emptying time (GET)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Symptom score
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Static and dynamic balance deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of end point events at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Percentage decrease in postoperative IL-1β
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Attenuation in elevated MMP-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Attenuation in elevated MMP-9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in IL-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes